Announcements Trials

Browse Landscape

Status

Completed 3 Unknown 1 Recruiting 1 Not yet recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Other hematologic neoplasm 4 Gastrointestinal 3 Sarcoma 2 Myeloid 2 Lymphoid 2 Gynecologic 2 Tumor-Agnostic 1 Thoracic 1 Head & Neck 1 Genitourinary 1 Dermatologic 1 Breast 1

Conditions

Uveal Melanoma 1 Communication 1

Interventions

Nivolumab 25 pembrolizumab 21 Ipilimumab 15 Temozolomide 13 toripalimab 12 Biopsy 10 Imiquimod 8 Cyclophosphamide 8 Dacarbazine 7 Blood Specimen Collection 7 camrelizumab 6 Chemotherapy, Adjuvant 6 trametinib 5 dabrafenib 5 atezolizumab 5 aldesleukin 5 Gene Expression Profiling 5 Cisplatin 5 Aminolevulinic Acid 5 fludarabine phosphate 4 fludarabine 4 durvalumab 4 binimetinib 4 apatinib 4 Tomography, Optical Coherence 4 Sorafenib 4 Photochemotherapy 4 Injections 4 Bevacizumab 4 tislelizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Interviews as Topic × Dermatologic × Clear all

NCT06073548 2023-10-10

SALOME Quali

Institut Curie

Uveal Melanoma, Communication

Data powered by HemOnc (CC BY 4.0) Colophon ⚡